Your browser doesn't support javascript.
loading
Characterization of VHL promoter variants in patients suspected of Von Hippel-Lindau disease.
Albanyan, Saleh; Giles, Rachel H; Gimeno, Enric Mocholi; Silver, Josh; Murphy, Jillian; Faghfoury, Hanna; Morel, Chantal F; Machado, Jerry; Kim, Raymond H.
Afiliação
  • Albanyan S; Division of Clinical and Metabolic Genetics, Department of Pediatrics, University of Toronto, The Hospital for Sick Children, Toronto, Canada.
  • Giles RH; Department of Nephrology and Hypertension, Regenerative Medicine Center Utrecht, University Medical Center Utrecht, The Netherlands.
  • Gimeno EM; Department of Cell Biology, Regenerative Medicine Center Utrecht, University Medical Center Utrecht, The Netherlands.
  • Silver J; Fred A Litwin Family Centre in Genetic Medicine, University Health Network, Canada; Department of Molecular Genetics, University of Toronto, Toronto, Canada.
  • Murphy J; Fred A Litwin Family Centre in Genetic Medicine, University Health Network, Canada; Department of Molecular Genetics, University of Toronto, Toronto, Canada.
  • Faghfoury H; Fred A Litwin Family Centre in Genetic Medicine, University Health Network, Canada; Division of Medical Oncology and Hematology, Department of Medicine, University of Toronto, Toronto, Canada.
  • Morel CF; Fred A Litwin Family Centre in Genetic Medicine, University Health Network, Canada; Division of Medical Oncology and Hematology, Department of Medicine, University of Toronto, Toronto, Canada.
  • Machado J; Prevention Genetics, Marshfield, WI, USA.
  • Kim RH; Fred A Litwin Family Centre in Genetic Medicine, University Health Network, Canada; Division of Medical Oncology and Hematology, Department of Medicine, University of Toronto, Toronto, Canada. Electronic address: raymond.kim@utoronto.ca.
Eur J Med Genet ; 62(3): 177-181, 2019 Mar.
Article em En | MEDLINE | ID: mdl-30006056
ABSTRACT
Von Hippel-Lindau (VHL) disease is a hereditary tumor syndrome in which carriers are at an increased risk of developing a variety of tumors in multiple organ systems. A clinical diagnosis of VHL is determined by the presence of specific clinical manifestations while a molecular genetic diagnosis results from a pathogenic variant in the VHL gene. The majority of mutations occur in VHL coding exons and DNA analysis of these regions has a reported sensitivity of nearly 100%. However, rare variants in the VHL gene promoter may be detected in some cases of suspected VHL disease. We report two cases where VHL promoter variants were detected and describe the role of multi-step mRNA and protein analysis in the diagnostic evaluation of these cases.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Proteína Supressora de Tumor Von Hippel-Lindau / Doença de von Hippel-Lindau / Mutação Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Proteína Supressora de Tumor Von Hippel-Lindau / Doença de von Hippel-Lindau / Mutação Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2019 Tipo de documento: Article